ライフサイエンスコーパス: adjuvant

1 ecific immunity in the absence of additional adjuvant.

2 of capsaicin, formalin or complete Freund's adjuvant.

3 o release chemokine's/cytokines as an immune-adjuvant.

4 ntigens which characterize Complete Freund's Adjuvant.

5 omes containing monophosphoryl lipid A as an adjuvant.

6 1 CN54gp140 protein (167mug)+/-R848 (167mug) adjuvant.

7 rier proteins and/or formulation with potent adjuvants.

8 malaria by co-administering it with vaccine adjuvants.

9 RT-associated NeuroAIDS and design effective adjuvants.

10 protection and synergetic effect between two adjuvants.

11 verage point in the rational design of novel adjuvants.

12 ry cytokine induction may qualify as vaccine adjuvants.

13 ch could, for instance, inform the choice of adjuvants.

14 otein (120 microg) with glucopyranosyl lipid adjuvant (5 microg) in 2% stable emulsion.

15 elling to paw injection of complete Freund's adjuvant, a model of peripheral inflammatory pain.

16 ery low doses and when administered with the adjuvants Abisco-100 and Matrix-M it elicits sterile pro

17 The synthetic glycans are found to have adjuvant activities in vivo.

18 This intrinsic adjuvant activity of the accompanying lipid cargo could

19 The adjuvant activity of the ligand was also confirmed in vi

20 Control mice received complete Freund adjuvant alone.

21 etanus toxoid (TT) conjugate formulated with adjuvants alum and CpG oligodeoxynucleotide (ODN) genera

22 Dendritic cells transduced with the adjuvant, an adenoviral vector encoding a dominant negat

23 ore potent booster vaccines than r30 with an adjuvant and a recombinant adenovirus vaccine expressing

24 eres (SHAS), which we suggest for the use as adjuvant and carrier in allergen-specific immunotherapy

25 RSV-G protein, that were boosted >10-fold by adjuvant and inversely correlated with viral load titers

26 but these were statistically significant for adjuvant and neoadjuvant trials only (OR, 1.05, 95% CI,

27 ring CpGs in VLP-based vaccines is that both adjuvants and antigens should be kept in close proximity

28 olymersome formulations against conventional adjuvants and licensed vaccines, including live attenuat

29 es can be positively modulated with chemical adjuvants and open the possibility of achieving full pro

30 2-positive breast cancer in the neoadjuvant, adjuvant, and metastatic settings; however, some patient

31 ections of peanut protein extract (PPE) with adjuvant, and then given PPE orally for 10 days, a seque

32 onses were superior to those induced by alum adjuvant, and they resulted in enhanced protection again

33 sult from systemic diffusion of many soluble adjuvants, and delivering multiple adjuvants at the same

34 e to support no overall outcome benefit from adjuvant anthracyclines in patients with early TOP2A-nor

35 Immunogenicity of the TLR8 agonist adjuvanted antigen 85B (Ag85B)/peptide 25-loaded BCG-mim

36 ne responses after topical application of an adjuvanted antigen formulation within a novel vaginal ri

37 d that FI-HSV-2 alone or in combination with adjuvants as well as adjuvanted subunit vaccines were su

38 cosolvents, cosurfactants, electrolytes, and adjuvants, as well as used in the creation of IL-support

39 se of 2-dose human papillomavirus 16/18 AS04-adjuvanted (AS04-HPV-16/18) vaccine schedules at months

40 y soluble adjuvants, and delivering multiple adjuvants at the same time to mimic the synergistic immu

41 accine immunization with protein antigen and adjuvant: B7 was required on DCs but was not required on

42 ously designed an antibody- and CMI-inducing adjuvant based on poly(dl-lactic-co-glycolic acid) (PLGA

43 Results Adjuvant bisphosphonates were found to reduce bone recur

44 National Surgical Adjuvant Breast and Bowel Project (NSABP) B-46-I/USOR 07

45 th or without bevacizumab (National Surgical Adjuvant Breast and Bowel Project C-08 trial).

46 Additionally, vaccine candidates adjuvanted by a robust formulation of the CpG oligonucle

47 discs coupled with antigen (Ag) peptides and adjuvants can markedly improve Ag/adjuvant co-delivery t

48 identification and/or engineering of vaccine adjuvants capable of supporting the development of SIgA

49 ds Data from 185 patients who relapsed after adjuvant carboplatin between January 1987 and August 201

50 S in these patients represent a challenge to adjuvant ccRCC drug development.

51 from rats with or without complete Freund's adjuvant (CFA) hindpaw inflammation, in response to elec

52 valbumin administered with complete Freund's adjuvant (CFA) or CFA alone.

53 e K/BxN serum-transfer and complete Freund's adjuvant (CFA)-evoked active immunization models compare

54 and survival outcomes associated with use of adjuvant chemoradiotherapy (CRT) for patients with resec

55 re is limited evidence to support the use of adjuvant chemotherapy (AC) after radical nephroureterect

56 endorses evaluating >/=12 lymph nodes (LNs), adjuvant chemotherapy (AC) for stage III patients, and A

57 Information regarding NAC, adjuvant chemotherapy (aCT), breast conserving surgery (

58 to conventional prognostic factors to guide adjuvant chemotherapy (CT) decisions.

59 Effectiveness of adjuvant chemotherapy according to time to initiation af

60 Adjuvant chemotherapy administered at different time poi

61 emcitabine to anthracycline and taxane-based adjuvant chemotherapy at this dose and schedule confers

62 To investigate receipt of adjuvant chemotherapy by age category (18-49, 50-64, and

63 herapies, and early tumor resection and (neo)adjuvant chemotherapy fails to improve a poor prognosis.

64 recommended to assess benefits and risks of adjuvant chemotherapy for each patient.

65 ong women undergoing non-anthracycline-based adjuvant chemotherapy for early-stage breast cancer, the

66 Adjuvant chemotherapy for resected early-stage non-small

67 Those receiving adjuvant chemotherapy had modestly higher doses ( P = .0

68 , gemcitabine has not been added to standard adjuvant chemotherapy in breast cancer for any subgroup.

69 d to evaluate the addition of bevacizumab to adjuvant chemotherapy in early-stage resected NSCLC.

70 rative therapy should be offered 6 months of adjuvant chemotherapy in the absence of medical or surgi

71 have pN2 disease have improved outcomes when adjuvant chemotherapy is administered before, rather tha

72 Adjuvant chemotherapy offers a survival benefit to a num

73 postoperative plasma, we observe evidence of adjuvant chemotherapy resistance and identify patients w

74 and under scenarios that reflected different adjuvant chemotherapy use.

75 P53/EGFR comutations in randomized trials of adjuvant chemotherapy versus observation.

76 persistent opioid use in patients receiving adjuvant chemotherapy was 15% to 21%, compared with 7% t

77 igh-risk stage II or stage III colon cancer, adjuvant chemotherapy with fluoropyrimidine monotherapy

78 k histopathologic features were treated with adjuvant chemotherapy, and no metastases were recorded i

79 e status (0 vs 1-2), previous neoadjuvant or adjuvant chemotherapy, and presence of brain metastases

80 to consider when making a recommendation for adjuvant chemotherapy, including tumor size, histopathol

81 ur multidisciplinary tumor board recommended adjuvant chemotherapy, postmastectomy radiation therapy,

82 01) and this was independent of stage, race, adjuvant chemotherapy, year of study, number of particip

83 For individuals with stage IB, adjuvant cisplatin-based chemotherapy is not recommended

84 biomarkers into surveillance guidelines and adjuvant clinical trials.

85 ptides and adjuvants can markedly improve Ag/adjuvant co-delivery to lymphoid organs and sustain Ag p

86 This novel adjuvant combination contributes to a more broadly prote

87 The triple adjuvant combination showed increased antigen-specific a

88 lity studies have demonstrated the safety of adjuvant concurrent chemoradiotherapy (CRT) for locally

89 Among innovative adjuvants conferring a Th1-shift, RNAdjuvant is a promis

90 NC with SM negative and no ECE, 47% received adjuvant CRT.

91 roximately 59% of surgical patients received adjuvant CRT.

92 We sought to determine whether adjuvant dabrafenib plus trametinib would improve outcom

93 using TLR ligands or house dust extracts as adjuvants developed mixed eosinophilic and neutrophilic

94 , whereas mice sensitized using proteases as adjuvants developed predominantly eosinophilic inflammat

95 Our results suggest that vaccine adjuvants differently modulate gp120-specific antibody r

96 even months post-immunization when using CDN adjuvant doses up to 100-fold lower than previous report

97 mulation of distant tumor growth and (b) use adjuvant drug therapies to block key identified mediator

98 The West German Study Group trial, ADAPT (Adjuvant Dynamic Marker-Adjusted Personalized Therapy Tr

99 IFN response has the potential to provide an adjuvant effect on vaccine potency, or, conversely, it m

100 y lymphoid tissues expand the scope of known adjuvant effects of PorB on the immune system.

101 were administered as a boost with poly-ICLC adjuvant either alone or coadministered with the NYVAC-K

102 ithout chemotherapy, supporting the study of adjuvant endocrine monotherapy in this group.

103 uggest that the opportunity to individualise adjuvant endocrine strategy accordingly, based on patien

104 e Previous studies suggest that adherence to adjuvant endocrine therapy (AET) for patients with breas

105 r have demonstrated the clinical benefits of adjuvant endocrine therapy (AET) in preventing recurrenc

106 owed by exemestane are reasonable options as adjuvant endocrine therapy in postmenopausal patients wi

107 If adjuvant endocrine therapy is indicated for breast cance

108 usion Cholesterol-lowering medication during adjuvant endocrine therapy may have a role in preventing

109 radiotherapy) and had completed 4-6 years of adjuvant endocrine therapy.

110 These data demonstrate that the adjuvanted Env protein boost is critical for protecting

111 d stage III colon cancers were randomized to adjuvant FOLFOX (folinic acid [leucovorin calcium], fluo

112 ntral Cancer Treatment Group N0147 trial) or adjuvant FOLFOX chemotherapy with or without bevacizumab

113 hetic vesicles as a new delivery vehicle and adjuvant for immunoprophylactic schistosomula vaccine ca

114 led matrice, are suitable platforms as novel adjuvants for cancer immunotherapy.

115 tioxidant therapies have gained attention as adjuvants for castration-resistant PCa.

116 Most FDA-approved adjuvants for infectious agents boost humoral but not ce

117 lead to promising host-directed therapeutic adjuvants for tuberculosis treatment.

118 gest that potent adjuvants, such as cationic adjuvant formulation 09, render low-dose vaccination a f

119 Here, we describe comprehensive adjuvant formulation development of the imidazoquinoline

120 Toll-like receptor (TLR) agonist adjuvant formulations have a demonstrated ability to bro

121 nclusively demonstrate the ability of 3M-052 adjuvant formulations to broaden responses to H5N1 HA ba

122 on were superior to unadjuvanted or MPL-alum-adjuvanted formulations at eliciting a robust cell-media

123 vent disease onset is limited by the lack of adjuvant-free experimental animal models.

124 Nexvax2 is an adjuvant-free mix of three peptides that include immunod

125 esponse gene 88 (MyD88), indicating that the adjuvants function in vivo via their known receptors, wi

126 chemotherapy in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial.

127 nt with this observation, patients receiving adjuvant gemcitabine (n = 107) with elevated serum gluco

128 ealthcare workers who received a single AS03-adjuvanted H1N1pdm09 vaccine in 2009 and subsequently ei

129 observed that using PC nanogel as a vaccine adjuvant had a dose-sparing effect and significantly enh

130 Despite decades of research very few vaccine-adjuvants have received FDA approval.

131 e points for 533 patients from the Herceptin Adjuvant (HERA) study who agreed to participate in this

132 The immunogenicity and safety of an adjuvanted herpes zoster subunit (HZ/su) vaccine when co

133 Using an emulsion of incomplete Freund's adjuvant (IFA) as a co-delivery vehicle, it was discover

134 n/AlbiVax than benchmark incomplete Freund's adjuvant (IFA).

135 isk of recurrence were randomized to receive adjuvant imatinib for 1 or 3 years.

136 ittle is known about whether the duration of adjuvant imatinib influences the prognostic significance

137 omal tumors (GISTs) treated with surgery and adjuvant imatinib.

138 se.Significance: Coordinated neoadjuvant and adjuvant immunotherapies reduce the risk of disease rela

139 n 31-fold greater than perhaps the strongest adjuvant in clinical trials (that is, CpG in Montanide).

140 uits are functional foods that can act as an adjuvant in the treatment of inflammatory conditions.

141 M2FA)-lysine adducts are immunogenic without adjuvants in mice.

142 the contribution of carrier determinants and adjuvants in promoting high-titer, long-lived antibody r

143 ts highlight the potential for such NP TLR L adjuvants in promoting robust and durable antibody respo

144 Thus, delivery of antigens and adjuvants in separate nanoparticles eliminates the need

145 ydroxide (AH) salts are the most widely used adjuvants in vaccine formulation.

146 oli (in presence and absence of oil-in-water adjuvant) in a preclinical RSV susceptible cotton rat ch

147 f TRPA1) and reversed CFA (Complete Freund's Adjuvant)-induced inflammation and thermal hyperalgesia.

148 ing that Ltab-Ncr3 is specific in regulating adjuvant-induced arthritis but not antigen-induced autoi

149 In the adjuvant-induced arthritis rat model, CHMFL-BTK-11 ameli

150 Intra-articular injection in an adjuvant-induced rat model of RA induces apoptosis of FL

151 ust mite (HDM), in the absence of additional adjuvants, influences offspring asthma development.

152 modalities of chemotherapy, requirements of adjuvant instrumental or surgical procedures, and organ

153 or synthetic lipopeptides are potent vaccine adjuvants, interacting with cell surface TLR2 heterodime

154 The EORTC 18071 phase 3 trial compared adjuvant ipilimumab with placebo in patients with stage

155 ve response induced in mice by this combined adjuvant is dependent upon TLR4 and TLR7 signaling via m

156 NCE Extending humoral immune responses using adjuvants is an important method to develop long-lasting

157 ts full dose.IMPORTANCE Development of novel adjuvants is needed to enhance immunogenicity to provide

158 ted tumor cells were surface engineered with adjuvant-loaded, biodegradable, biocompatible, polymeric

159 of mice when either group was immunized with adjuvanted low-dose A(H5N1) subvirion vaccine.

160 Our results suggest that HIV vaccine adjuvants may differentially modulate immune responses i

161 xploration of EC therapies that can serve as adjuvant modalities to enhance HSC engraftment and accel

162 neuropathic pain or in the Complete Freund's adjuvant model of inflammatory pain.

163 orbed grass pollen allergoids containing the adjuvant monophosphoryl lipid A (MPL((R)) ); 51 control

164 and economically manufactured microparticle adjuvants, namely strontium-doped hydroxyapatite porous

165 capsulated cGAMP represents a potent vaccine adjuvant of humoral and cellular immunity.

166 ith hormone receptor-positive breast cancer, adjuvant OFS combined with tamoxifen or exemestane produ

167 Out of 11 adjuvants, only two, Abisco((R))-100 and CoVaccineHT(TM)

168 safety profile in the clinic when used as an adjuvant or an immunotherapeutic agent-to rectify the mu

169 abine, with stratification by sex and use in adjuvant or neoadjuvant vs palliative setting.

170 ent a prognostic parameter when deciding for adjuvant or palliative chemotherapy.

171 IRE plus chemotherapy in the neoadjuvant and adjuvant or second-line setting compared with more widel

172 , or 100 microg of GEN-003, antigens without adjuvant, or placebo.

173 g brood to both an organosilicone surfactant adjuvant (OSS) commonly used on many agricultural crops

174 challenge after immunization with PC nanogel-adjuvanted pH1N1 vaccine.

175 Localised adjuvant potent topical corticosteroids (<30 g per week)

176 of ultrasonic debridement, STC and GPAP with adjuvant Povidone-iodine led to significant clinical imp

177 f ultrasonic debridement, STC, and GPAP with adjuvant povidone-iodine led to significant clinical imp

178 ndicate that Salmonella flagellin has unique adjuvant properties that improve SseB-mediated protectiv

179 l development of new molecules with powerful adjuvant properties.

180 To determine the optimal adjuvant radiation therapy (RT) dose following resection

181 She received adjuvant radiation therapy and initiated letrozole, with

182 Trial 0116 (Phase III trial of postoperative adjuvant radiochemotherapy for high risk gastric and gas

183 nted oncologic benefit, use of postoperative adjuvant radiotherapy (aRT) in patients with prostate ca

184 Purpose To evaluate the effect of adjuvant radiotherapy (RT) after breast conservation sur

185 Adjuvant radiotherapy (RT) in breast cancer (BC) is ofte

186 lant SR was higher in women who had received adjuvant radiotherapy.

187 eatures, and patients with WDTC treated with adjuvant RAI should be monitored for myeloid malignancie

188 ed that immunization of infants with an MF59-adjuvanted recombinant gp120 vaccine induced higher-magn

189 enges plague clinical translation of vaccine-adjuvants: reducing acute toxicities that result from sy

190 vs or >/=4 positive nodes), and trastuzumab adjuvant regimen (given sequentially vs concurrently wit

191 The ARISER trial (Adjuvant Rencarex Immunotherapy Phase 3 Trial to Study E

192 nd GPI-anchored CCL28 as antigen and mucosal adjuvant, respectively, when immunized intranasally in m

193 matopoietic stem-cell transplant followed by adjuvant retinoid differentiation treatment.

194 Understanding an adjuvant's mechanism of action is a critical component f

195 red to HER2(+) breast cancer patients in the adjuvant setting suggest synergy between the vaccines an

196 the metastatic and, to a limited extent, the adjuvant setting.

197 sting of chemotherapy in the neoadjuvant and adjuvant settings, along with surgical intervention.

198 monstrate here that a combined TLR4 and TLR7 adjuvant signals via the appropriate receptors and the M

199 tumor stimulation and can be suppressed with adjuvant STAT3 inhibitors.

200 represent a stratification factor for future adjuvant studies.

201 or in combination with adjuvants as well as adjuvanted subunit vaccines were successful in the induc

202 Adjuvants such as micro- and nanoparticles are often add

203 These data suggest that potent adjuvants, such as cationic adjuvant formulation 09, ren

204 A cohort of patients who intended to receive adjuvant sunitinib for 6 months was compared with instit

205 ategory (P = 0.022), gender (P = 0.040), and adjuvant sunitinib in patients aged <60 years (P = 0.004

206 ll renal cancer (ccRCC) in the ASSURE trial (adjuvant sunitinib or sorafenib vs placebo in resected u

207 recently published results of a 750-patient adjuvant sunitinib trial showing improved disease-free s

208 nts with primary uveal melanoma who received adjuvant sunitinib with institutional controls.

209 ical risk to inform decisions on withholding adjuvant systemic chemotherapy.

210 effectiveness of liver resection followed by adjuvant systemic therapy relative to systemic therapy a

211 Conclusion Adjuvant systemic treatments may have the greatest benef

212 known as MITA, MPYS, or ERIS) is an exciting adjuvant target due to its role in cyclic dinucleotide (

213 ular bacterial and viral DNA and a promising adjuvant target in innate immune cells; more recently ST

214 Gy in 33 fractions of 1.8 Gy) alone or with adjuvant temozolomide (12 4-week cycles of 150-200 mg/m(

215 INTERPRETATION: Adjuvant temozolomide chemotherapy was associated with a

216 the use of radiotherapy with concurrent and adjuvant temozolomide in adults with non-co-deleted anap

217 ractionated radiotherapy with concurrent and adjuvant temozolomide is the standard of care after biop

218 The addition of concurrent and adjuvant temozolomide to hypofractionated radiotherapy s

219 zolomide 75 mg/m(2) per day, with or without adjuvant temozolomide.

220 esults demonstrate that organosilicone spray adjuvants that are considered biologically inert potenti

221 ration vaccine candidates may concentrate on adjuvants that modulate the immune system to support enh

222 ead clinical use of EE as oral contraceptive adjuvant, the impact of these estrogenic endocrine disru

223 f insoluble aluminum salts (alum) as vaccine adjuvants, the molecular mechanisms underpinning Ag-spec

224 us, DPP4 inhibitors may be used as potential adjuvant therapeutic agents to treat increased vascular

225 lls, and could potentially be utilized as an adjuvant therapeutic to enhance radiation sensitivity.

226 itis are likely to be multidimensional, with adjuvant therapies aimed at modifying the immune respons

227 Adjuvant therapies aimed at reducing the immune response

228 als were grouped considering neoadjuvant and adjuvant therapies and surgery alone, neoadjuvant therap

229 5% CI 0.76-0.90), whereas surgery along with adjuvant therapies showed no significant survival advant

230 al (OS) could expedite the evaluation of new adjuvant therapies.

231 roved survival and a reduction in subsequent adjuvant therapies.

232 sk stratification, and select candidates for adjuvant therapies.

233 Simple cholecystectomy with adjuvant therapy appears to be superior to extended rese

234 To assess if simple cholecystectomy with adjuvant therapy could provide outcomes comparable to ex

235 lining influence of axillary nodal status on adjuvant therapy decision-making, ongoing clinical trial

236 Adjuvant therapy followed national standards.

237 C and this approach might be promising as co-adjuvant therapy for cystic fibrosis.

238 Purpose Adjuvant therapy for intermediate-risk and high-risk loc

239 tus for survival outcome after resection and adjuvant therapy for pancreatic cancer.

240 sphonates and other bone-modifying agents as adjuvant therapy for patients with breast cancer.

241 s setting and should not be considered as an adjuvant therapy for patients with resected early-stage

242 verteporfin should be further explored as an adjuvant therapy for the treatment of glioblastoma.

243 tial role for selenium supplementation as an adjuvant therapy in CML.

244 nstrate that CXCR7 is a potential target for adjuvant therapy in combination with androgen deprivatio

245 atic review of the literature, investigating adjuvant therapy in resected non-small-cell lung cancers

246 Adjuvant therapy prolongs survival after resection of T2

247 rrently integrated into prognostic models or adjuvant therapy trials.

248 Adjuvant therapy was defined as chemotherapy, with or wi

249 one propensity score matching for receipt of adjuvant therapy was used to account for potential selec

250 At the 5-year follow-up, 1 year of extended adjuvant therapy with neratinib, administered after chem

251 three stratification criteria: previous (neo)adjuvant therapy, chemotherapy-free interval, and tumour

252 In the context of adjuvant therapy, the resection margin status remains an

253 a subgroup of UR patients who also received adjuvant therapy-for early-stage resectable pancreatic a

254 cebo (1:1:1) for the duration of trastuzumab adjuvant therapy.

255 A total of 438 (85.9%) received adjuvant therapy.

256 rgery or on pathology; 31.8% (2168) received adjuvant therapy.

257 as definitive therapy or as a postoperative adjuvant therapy.

258 are the effect of lorazepam vs placebo as an adjuvant to haloperidol for persistent agitation in pati

259 ganism, encapsulated into Lp functions as an adjuvant to induce a robust specific CTL response.

260 Although CpGs are candidates for adjuvants to boost innate and adaptive immunity, our und

261 all molecules may be explored as therapeutic adjuvants to improve disease outcomes during intracellul

262 represent a vanguard of new immunometabolic adjuvants to safely enhance the efficacy of cancer immun

263 zithromycin and doxycycline may be effective adjuvants to standard antiacanthamoebal chemotherapy by

264 erapy and molecularly-targeted therapies, as adjuvants to surgery, have been described in individual

265 y linked) to ensure delivery of antigens and adjuvants to the same APCs.

266 As immunometabolic adjuvants to widen therapeutic windows, IDO inhibitors m

267 age, largest basal diameter, and the use of adjuvant transpupillary thermotherapy (TTT).

268 INTERPRETATION: 1 year of adjuvant trastuzumab after chemotherapy for patients wit

269 2 years of adjuvant trastuzumab did not improve disease free-surviv

270 burden may augment staging and better inform adjuvant treatment decisions.

271 ne is not considered a standard agent in the adjuvant treatment of early breast cancer.

272 chemotherapy with or without trastuzumab for adjuvant treatment of node-positive, human epidermal gro

273 rpose Gemcitabine is standard of care in the adjuvant treatment of resectable pancreatic ductal adeno

274 With the variety of surgical and adjuvant treatment options available, there has been gre

275 Adjuvant treatment should be initiated within 8 weeks of

276 therapy to determine the association between adjuvant treatment timing and efficacy.

277 ne analog (6-diazo-5-oxo-L-norleucine) as an adjuvant treatment to sensitize chemoresistant pancreati

278 Systemic adjuvant treatment was sparsely used (8%).

279 15% of the relapses occurred > 3 years after adjuvant treatment, a minimum of 5 years follow-up is re

280 An urgent need exists for adjuvant treatments that can enhance or replace current

281 ble renal cell carcinoma [RCC]), the largest adjuvant trial published to date.

282 We observed some improvement in accrual to adjuvant trials but worsening of accrual for neoadjuvant

283 Methods In a series of three adjuvant trials, women were randomly assigned to TC for

284 nital tract with the optimized GC-coated LPN adjuvant upon nasal immunization of mice with the recomb

285 Adjuvant use of bisphosphonates can reduce the incidence

286 Adjuvant use of combination therapy with dabrafenib plus

287 with BRAF V600E or V600K mutations than the adjuvant use of placebo and was not associated with new

288 Our results suggest that adjuvanted vaccination in populations where PEM is endem

289 malaria vaccines through assessments of new adjuvants, vaccination platforms, and antigens.

290 NP-adjuvanted vaccines induced antigen-specific, long-lived

291 Although alum-adjuvanted vaccines induced modest costimulatory molecul

292 NP-adjuvanted vaccines induced robust innate responses, ant

293 sponses compared to those achieved with alum-adjuvanted vaccines.

294 es in heterologous response were seen in the adjuvanted versus nonadjuvanted groups.

295 Freund's complete adjuvant were used to induce joint inflammation.

296 virus-like particle (VLP) vaccine candidate adjuvanted with alum and monophosphoryl lipid A (MPL), b

297 trates that mucosal administration of CTH522 adjuvanted with chitosan-coated LPNs represents a promis

298 Our previous work has shown that antigens adjuvanted with ligands specific for Toll-like receptor

299 owever, the sequential order of allergen and adjuvant within a fusion protein determines its immunolo

300 ours could predict the treatment outcomes of adjuvant zoledronic acid.